IgA antibodies against β2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality
Identificadores
URI: http://hdl.handle.net/20.500.12020/1280ISSN: 1523-1755
DOI: 10.1038/ki.2011.477
Autor/es
Serrano, Antonio; Garcia, Florencio; Serrano, Manuel; Ramirez, Elisa; Alfaro, F Javier; [et al.]Fecha
2012Tipo de documento
articleÁrea/s de conocimiento
Ciencias BiomédicasResumen
Cardiovascular complications are the most important cause
of death in patients on dialysis with end-stage renal disease.
Antibodies reacting with b-glycoprotein I seem to play a
pathogenic role in antiphospholipid syndrome and stroke
and are involved in the origin of atherosclerosis. Here
we evaluated the presence of anticardiolipin and anti-bglycoprotein
I antibodies together with other vascular
risk factors and their relationship with mortality and
cardiovascular morbidity in a cohort of 124 hemodialysis
patients prospectively followed for 2 years. Of these,
41 patients were significantly positive for IgA anti-bglycoprotein
I, and the remaining had normal values. At 24
months, overall and cardiovascular mortality and thrombotic
events were all significantly higher in patients with high antib-
glycoprotein I antibodies. Multivariate analysis using Cox
regression modeling found that age, hypoalbuminemia, use
of dialysis catheters, and IgA b-glycoprotein I antibodies were
independent risk factors for death. Thus, IgA antibodies to
b-glycoprotein I are detrimental to the clinical outcome of
hemodialysis patients.